Effects of 5-Fluorouracil (5-FU) Ointment on Normal and Diseased Skin Histological Findings and Deep Action

Klostermann, G. F.

doi:10.1159/000252594

Cited by 17 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imiquimod is also prescribed to patients with necessitated BCC syndrome [58,59]. Topical 5-FU is a topical therapeutic option for sBCCs and is usually reserved for them [60][61][62]. An RCT found that at the 12-month follow-up, 5-FU and imiquimod were statistically similar in treating sBCC [63].…”

Section: Topical Therapiesmentioning

confidence: 99%

Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management

Naik¹,

Desai

2022

Oncol Ther

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common, accounting for 80-90% of skin cancers. It arises from the basal layer of the epidermis and its appendages. A complex interplay of environmental, phenotypic and genetic variables leads to the development of BCC. Literature has documented several clinical subtypes of BCC, the most common of which are nodular, superficial and morpheaform. Expeditious diagnosis and analysis are essential for improving the outcome of BCC. Preventive measures, particularly when implemented in childhood and adolescence, may play a critical role. Due to its low metastatic potential, treatment for BCC mostly focuses on local management. The standard treatment of basal cell carcinoma involved complete removal of the lesion by excision or Mohs surgery. In special circumstances, basal cell carcinoma can be treated with cryosurgery, electrodesiccation and curettage, topical medications and photodynamic therapy. This review aimed to evaluate the contemporary diagnosis and management of basal cell carcinoma.

show abstract

Section: Topical Therapiesmentioning

confidence: 99%

Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management

Naik¹,

Desai

2022

Oncol Ther

View full text Add to dashboard Cite

show abstract

“…Because the cure rate is considered lower than surgery or radiation therapy, the National Comprehensive Cancer Network (NCCN) guidelines reserve this therapy in patients with low-risk sBCC where surgery or radiation is contraindicated or impractical [20]. Because the percutaneous penetration of 5-FU is variable and limited [29][30][31], its use is recommended only for sBCC and not other histologic types of BCC. • Topical 5-FU is applied twice daily for no <6 weeks if not occluded or combined with curettage.…”

Section: -Fluorouracilmentioning

confidence: 99%

Skin Cancer and the Solid Organ Transplant Recipient

Patel

Liégeois

2008

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Organ transplant recipients (OTRs) are living longer in setting of improved medical immunosuppression. The most common late post-transplant complication includes a variety of malignant and premalignant cutaneous tumors. Aggressive skin cancers are common in this population. Clinical and pathologic correlation is essential in choosing the appropriate treatment for the various subtypes of skin cancer in OTR. Approaches include risk assessment for other skin tumors, treatment of malignancy, and prevention. Few prospective or retrospective studies with multivariate analysis exist and therefore opinion largely dominates treatment recommendations. Treatment aims: (i) The mainstay of treatment focuses on total removal (excision) or mechanical destruction of the tumor. In the appropriate clinical scenario, a skin cancer should be removed or treated fully. (ii) Treatment modality is dependant upon low- vs high-risk tumors and tumor type. (iii) Utilize excision with margin control, either by permanent or frozen (Mohs) technique, for large tumors and tumors in high-risk sites. (iv) New treatment modalities include immune modulators, topical photodynamic therapy, and drugs targeting genetic defects. (v) Education on skin cancer prevention should target all the age groups.

show abstract

“…Premalignant conditions, such as carcinoma in situ (Table 2), Bowen's disease, actinic keratosis and xeroderma pigmentosum, may spread over a large area or arise in several places simultaneously and are therefore difficult to treat surgically and form a good indication for the local application of 5-Fu (Klein, 1968;Goette, 1981). The reaction of the abnormal epithelial cells to the cytostatic gives rise to erythema, bullae, erosion, ulceration and necrosis of the skin, followed subsequently by re-epithelization and normalization (Klein, 1968;Klosterman, 1970).…”

mentioning

confidence: 99%

Topical application of 5-Fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid

1986

View full text Add to dashboard Cite

Local application of 5-Fluorouracil was practised on 5 patients. In 3 patients with multiple premalignant oculo-cutaneous lesions, two of whom had also premalignant epibulbar lesions, local 5% 5-Fu cream and/or 1% 5-Fu eyedrops were applied. In 2 other patients who had only premalignant lesions on the cornea and conjunctiva, 1% 5-Fu eyedrops were used only. In animal experiments 1% 5-Fu was not found to cause any damage to normal corneal and conjunctival epithelium. The frequency of the applications and the duration of the treatment were dependent on the location and extent of the lesions. Except for easily treatable lesions, caused by the separation of the tumour epithelium, no complications of local 5-Fu treatment were seen. The visual acuity improved in all 4 patients in whom the cornea was affected. In these premalignant conditions the diagnosis and assessment of the therapy were based on exfoliative cytology and biopsies.

show abstract

Effects of 5-Fluorouracil (5-FU) Ointment on Normal and Diseased Skin Histological Findings and Deep Action

Cited by 17 publications

References 0 publications

Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management

Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management

Skin Cancer and the Solid Organ Transplant Recipient

Topical application of 5-Fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid

Contact Info

Product

Resources

About